Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


20.03.2017

1 AJR Am J Roentgenol
1 Am J Clin Oncol
1 Arch Bronconeumol
1 BMC Cancer
2 Cancer Chemother Pharmacol
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Sci
1 Chest
1 Clin Cancer Res
1 Int J Cancer
2 J Clin Oncol
1 J Thorac Cardiovasc Surg
2 J Thorac Oncol
1 Lancet Oncol
15 Lung Cancer
2 Lung Cancer (Auckl)
1 Mol Cancer Ther
1 Oncogene
8 Oncol Rep
2 PLoS One
1 Proc Natl Acad Sci U S A
1 Science


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. MING H, Fang L, Gao J, Li C, et al
    Antitumor Effect of Nanoparticle 131I-Labeled Arginine-Glycine-Aspartate-Bovine Serum Albumin-Polycaprolactone in Lung Cancer.
    AJR Am J Roentgenol. 2017 Mar 16:1-11. doi: 10.2214/AJR.16.16947.
    PubMed     Text format     Abstract available


    Am J Clin Oncol

  2. BECKER DJ, Levy BP, Gold HT, Sherman SE, et al
    Influence of Extent of Lymph Node Evaluation on Survival for Pathologically Lymph Node Negative Non-Small Cell Lung Cancer.
    Am J Clin Oncol. 2017 Mar 15. doi: 10.1097/COC.0000000000000379.
    PubMed     Text format     Abstract available


    Arch Bronconeumol

  3. COROMINAS D, Vollmer I, Paredes P
    Pulmonary Tumor Embolism due to Cardiac Metastasis of Lung Cancer.
    Arch Bronconeumol. 2017 Mar 6. pii: S0300-2896(17)30018.
    PubMed     Text format    


    BMC Cancer

  4. SULLIVAN FM, Farmer E, Mair FS, Treweek S, et al
    Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT(R)-Lung Test (ECLS): study protocol for a randomized controlled trial.
    BMC Cancer. 2017;17:187.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  5. HATA A, Katakami N, Hattori Y, Tanaka K, et al
    Pemetrexed monotherapy for chemo-naive elderly (aged >/=80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).
    Cancer Chemother Pharmacol. 2017 Mar 9. doi: 10.1007/s00280-017-3259.
    PubMed     Text format     Abstract available

  6. ZHOU J, Dong F, Cui F, Xu R, et al
    The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Mar 13. doi: 10.1007/s00280-017-3269.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  7. BOLDRY EJ, Patel YM, Kotapati S, Esades A, et al
    Genetic Determinants of 1,3-Butadiene Metabolism and Detoxification in Three Populations of Smokers with Different Risks of Lung Cancer.
    Cancer Epidemiol Biomarkers Prev. 2017 Mar 14. pii: cebp.0838.2016.
    PubMed     Text format     Abstract available


    Cancer Sci

  8. TODE N, Kikuchi T, Sakakibara T, Hirano T, et al
    Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer.
    Cancer Sci. 2017 Mar 13. doi: 10.1111/cas.13233.
    PubMed     Text format     Abstract available


    Chest

  9. RAVENEL JG, Tanner NT, Silvestri GA
    Viewing All the Trees in the Forest: The Importance of Reporting Abnormal Findings on CT Scan When Screening for Lung Cancer.
    Chest. 2017;151:525-526.
    PubMed     Text format    


    Clin Cancer Res

  10. PEREIRA C, Gimenez-Xavier P, Pros E, Pajares MJ, et al
    Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.
    Clin Cancer Res. 2017 Mar 16. doi: 10.1158/1078-0432.CCR-16-1946.
    PubMed     Text format     Abstract available


    Int J Cancer

  11. YANG Z, Hackshaw A, Feng Q, Fu X, et al
    Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
    Int J Cancer. 2017 Mar 14. doi: 10.1002/ijc.30691.
    PubMed     Text format     Abstract available


    J Clin Oncol

  12. DESS RT, Sun Y, Matuszak MM, Sun G, et al
    Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 Mar 16:JCO2016716142. doi: 10.1200/JCO.2016.71.6142.
    PubMed     Text format     Abstract available

  13. TAMURA T, Kiura K, Seto T, Nakagawa K, et al
    Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.
    J Clin Oncol. 2017 Mar 15:JCO2016705749. doi: 10.1200/JCO.2016.70.5749.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  14. CZARNECKA-KUJAWA K, Rochau U, Siebert U, Atenafu E, et al
    Cost-effectiveness of mediastinal lymph node staging in non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2017 Feb 9. pii: S0022-5223(17)30176.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  15. TEKATLI H, van 't Hof S, Nossent EJ, Dahele M, et al
    Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
    J Thorac Oncol. 2017 Mar 7. pii: S1556-0864(17)30180.
    PubMed     Text format     Abstract available

  16. PELED N, Roisman LC, Miron B, Pfeffer R, et al
    Sub-Clonal Therapy by two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-mutated Lung Cancer.
    J Thorac Oncol. 2017 Mar 7. pii: S1556-0864(17)30182.
    PubMed     Text format    


    Lancet Oncol

  17. BROWER V
    Pravastatin has no advantage in small-cell lung cancer.
    Lancet Oncol. 2017 Mar 9. pii: S1470-2045(17)30184.
    PubMed     Text format    


    Lung Cancer

  18. BAGLEY SJ, Kothari S, Aggarwal C, Bauml JM, et al
    Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2017;106:1-7.
    PubMed     Text format     Abstract available

  19. DURIEUX V, Coureau M, Meert AP, Berghmans T, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature.
    Lung Cancer. 2017;106:102-109.
    PubMed     Text format     Abstract available

  20. OU SI, Lee TK, Young L, Fernandez-Rocha MY, et al
    Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
    Lung Cancer. 2017;106:110-114.
    PubMed     Text format     Abstract available

  21. JONES BS, Jerome MS, Miley D, Jackson BE, et al
    Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2017;106:125-130.
    PubMed     Text format     Abstract available

  22. KASAHARA N, Kenmotsu H, Serizawa M, Umehara R, et al
    Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2017;106:138-144.
    PubMed     Text format     Abstract available

  23. IRIKI T, Ohnishi K, Fujiwara Y, Horlad H, et al
    The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation.
    Lung Cancer. 2017;106:22-32.
    PubMed     Text format     Abstract available

  24. HOLBRECHTS S, Gorham J, Sideris S, Meert AP, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes.
    Lung Cancer. 2017;106:93-101.
    PubMed     Text format     Abstract available

  25. BENTEA G, Sculier C, Grigoriu B, Meert AP, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system.
    Lung Cancer. 2017;106:83-92.
    PubMed     Text format     Abstract available

  26. FUJIWARA A, Shintani Y, Funaki S, Kawamura T, et al
    Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer.
    Lung Cancer. 2017;106:8-16.
    PubMed     Text format     Abstract available

  27. KIM DW, Garon EB, Jatoi A, Keefe DM, et al
    Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
    Lung Cancer. 2017;106:76-82.
    PubMed     Text format     Abstract available

  28. REMON J, Pardo N, Martinez-Marti A, Cedres S, et al
    Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
    Lung Cancer. 2017;106:70-75.
    PubMed     Text format     Abstract available

  29. LIU M, Wampfler JA, Dai J, Gupta R, et al
    Chest wall resection for non-small cell lung cancer: A case-matched study of postoperative pulmonary function and quality of life.
    Lung Cancer. 2017;106:37-41.
    PubMed     Text format     Abstract available

  30. MADDISON P
    Effects of aspirin on small-cell lung cancer mortality and metastatic presentation.
    Lung Cancer. 2017;106:67-69.
    PubMed     Text format     Abstract available

  31. SIMMONS VN, Gray JE, Schabath MB, Wilson LE, et al
    High-risk community and primary care providers knowledge about and barriers to low-dose computed topography lung cancer screening.
    Lung Cancer. 2017;106:42-49.
    PubMed     Text format     Abstract available

  32. HALPENNY DF, McEvoy S, Li A, Hayan S, et al
    Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics.
    Lung Cancer. 2017;106:33-36.
    PubMed     Text format     Abstract available


    Lung Cancer (Auckl)

  33. SOMASUNDARAM A, Burns TF
    Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.
    Lung Cancer (Auckl). 2017;8:1-11.
    PubMed     Text format     Abstract available

  34. THAKUR MK, Wozniak AJ
    Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma.
    Lung Cancer (Auckl). 2017;8:13-19.
    PubMed     Text format     Abstract available


    Mol Cancer Ther

  35. WILLUDA J, Linden L, Lerchen HG, Kopitz C, et al
    Preclinical Anti-Tumor Efficacy of BAY 1129980 - a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-small Cell Lung Cancer.
    Mol Cancer Ther. 2017 Mar 14. pii: molcanther.0474.2016.
    PubMed     Text format     Abstract available


    Oncogene

  36. BOUILLEZ A, Rajabi H, Jin C, Samur M, et al
    MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
    Oncogene. 2017 Mar 13. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    Oncol Rep

  37. HAN X, Tian Y, Tian D
    Tumor metastatic promoter ABCE1 interacts with the cytoskeleton protein actin and increases cell motility.
    Oncol Rep. 2016;35:3623-9.
    PubMed     Text format     Abstract available

  38. OLBROMSKI M, Grzegrzolka J, Jankowska-Konsur A, Witkiewicz W, et al
    MicroRNAs modulate the expression of the SOX18 transcript in lung squamous cell carcinoma.
    Oncol Rep. 2016;36:2884-2892.
    PubMed     Text format     Abstract available

  39. KIM KH, Chae JI, Oh H, Cho JH, et al
    Manumycin A induces apoptosis in malignant pleural mesothelioma through regulation of Sp1 and activation of the mitochondria-related apoptotic pathway.
    Oncol Rep. 2016;36:117-24.
    PubMed     Text format     Abstract available

  40. CHEN J, Lu X, Lu C, Wang C, et al
    13-Methyl-palmatrubine induces apoptosis and cell cycle arrest in A549 cells in vitro and in vivo.
    Oncol Rep. 2016;36:2526-2534.
    PubMed     Text format     Abstract available

  41. WANG X, Liu Y, Dai L, Liu Q, et al
    Foxp3 downregulation in NSCLC mediates epithelial-mesenchymal transition via NF-kappaB signaling.
    Oncol Rep. 2016;36:2282-8.
    PubMed     Text format     Abstract available

  42. ZHUANG X, Qiao T, Xu G, Yuan S, et al
    Combination of nadroparin with radiotherapy results in powerful synergistic antitumor effects in lung adenocarcinoma A549 cells.
    Oncol Rep. 2016;36:2200-6.
    PubMed     Text format     Abstract available

  43. CHEN J, Hu L, Chen J, Wu F, et al
    Low expression lncRNA RPLP0P2 is associated with poor prognosis and decreased cell proliferation and adhesion ability in lung adenocarcinoma.
    Oncol Rep. 2016;36:1665-71.
    PubMed     Text format     Abstract available

  44. LI JY, Yu J, Du XS, Zhang HM, et al
    Safflower polysaccharide induces NSCLC cell apoptosis by inhibition of the Akt pathway.
    Oncol Rep. 2016;36:147-54.
    PubMed     Text format     Abstract available


    PLoS One

  45. YANG Y, Qiu S, Qian L, Tian Y, et al
    OCF can repress tumor metastasis by inhibiting epithelial-mesenchymal transition involved in PTEN/PI3K/AKT pathway in lung cancer cells.
    PLoS One. 2017;12:e0174021.
    PubMed     Text format     Abstract available

  46. AMERATUNGA M, Asadi K, Lin X, Walkiewicz M, et al
    PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.
    PLoS One. 2016;11:e0153954.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A


  47. Correction for Jeon et al., A set of NF-kappaB-regulated microRNAs induces acquired TRAIL resistance in Lung cancer.
    Proc Natl Acad Sci U S A. 2017 Mar 13. pii: 201701795.
    PubMed     Text format    


    Science

  48. MAYERS JR, Torrence ME, Danai LV, Papagiannakopoulos T, et al
    Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers.
    Science. 2016;353:1161-5.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: